Home
|
Learning Center
|
中文版
Publications
站内成果搜索:
搜索
Ranibizumab玻璃体内注射治疗病理性近视脉络膜新生血管研究进展
Ranibizumab辅助玻璃体手术治疗增殖性糖尿病视网膜病变的临床观察
Ranibizumab治疗继发于AMD以外的脉络膜新生血管的临床观察
Ranibizumab玻璃体腔内注射治疗Ⅱ型视盘血管炎1例
Ranibizumab for High-Risk Proliferative Diabetic Retinopathy: An Exploratory Randomized Controlled Trial
Ranibizumab for the treatment of wet AMD: a summary of real-world studies
Ranibizumab or Bevacizumab for Neovascular Age-Related Macular Degeneration According to the Lucentis Compared to Avastin Study Treat-and-Extend Protocol Two-Year Results
Ranitidine-induced anaphylaxis: clinical features, cross-reactivity, and skin testing
Ranitidine reduced levodopa-induced dyskinesia by remodeling neurochemical changes in hemiparkinsonian model of rats
Ranibizumab for Branch Retinal Vein Occlusion Associated Macular Edema Study (RABAMES): six-month results of a prospective randomized clinical trial
Ranibizumab vs. aflibercept for wet age-related macular degeneration: network meta-analysis to understand the value of reduced frequency dosing
Ranitidine interference with standard amphetamine immunoassay
Ranibizumab Versus Mitomycin C in Primary Trabeculectomy - A Pilot Study
Ranibizumab 0.5 mg for Diabetic Macular Edema with Bimonthly Monitoring after a Phase of Initial Treatment 18-Month, Multicenter, Phase IIIB RELIGHT Study
Ranibizumab and aflibercept for the treatment of wet age-related macular degeneration
Ranibizumab and Aflibercept: Intraocular Pharmacokinetics and Their Effects on Aqueous VEGF Level in Vitrectomized and Nonvitrectomized Macaque Eyes
Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration.
Ranibizumab for exudative age-related macular degeneration: 24-month outcomes from a single-centre institutional setting
Ranitidine induced hepatitis
Ranitidine as an alcohol dehydrogenase inhibitor in acute methanol toxicity in rats
Ranibizumab for retinal angiomatous proliferation in age-related macular degeneration
Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study
Ranirestat has a stronger inhibitory activity on aldose reductase and suppresses inflammatory reactions in high glucose-exposed endothelial cells
Ranibizumab as needed therapy for wet age-related macular degeneration combined with serous pigment epithelial detachment
Ranibizumab versus bevacizumab for the treatment of idiopathic choroidal neovascularization: 2-Year results
Ranibizumab治疗糖尿病性黄斑水肿短期疗效观察
Ranibizumab injection for diabetic macular edema: meta-analysis of systemic safety and systematic review
Ranibizumab: A Review of Its Use in the Treatment of Neovascular Age-Related Macular Degeneration
Ranibizumab treatment for neovascular age-related macular degeneration in patients with good baseline visual acuity (better than 6/12): 12-month outcomes
Ranibizumab for choroidal neovascular membrane in a rare case of Bietti's crystalline dystrophy: A case report
Ranibizumab for age-related macular degeneration
Ranibizumab and Risk of Hospitalisation for Ischaemic Stroke and Myocardial Infarction in Patients with Age-Related Macular Degeneration: A Self-Controlled Case-Series Analysis
Ranibizumab Treatment for Choroidal Neovascularization from Causes Other than Age-Related Macular Degeneration and Pathological Myopia
Ranibizumab in the treatment of choroidal neovascularisation due to age-related macular degeneration: an optical coherence tomography and multifocal electroretinography study
Ranibizumab in retinal vein occlusion: treatment recommendations by an expert panel
Ranibizumab for Diabetic Macular Edema Results from 2 Phase III Randomized Trials: RISE and RIDE
Ranibizumab: A Review of its Use in Myopic Choroidal Neovascularization
Ranibizumab Treatment for Choroidal Neovascularization Secondary to Causes Other than Age-Related Macular Degeneration with Good Baseline Visual Acuity
Ranibizumab therapy for choroidal neovascularization secondary to non-age-related macular degeneration causes
Ranibizumab in retinal angiomatous proliferation (RAP): influence of RAP stage on visual outcome
Ranibizumab for retinal angiomatous proliferation
Ranibizumab for Exudative Age-Related Macular Degeneration in Eyes Previously Treated With Alternative Vascular Endothelial Growth Factor Inhibitors
Ranibizumab for neovascular age-related macular degeneration
Ranibizumab for Choroidal Neovascularization Secondary to Causes Other Than Age-Related Macular Degeneration: A Phase I Clinical Trial
Ranibizumab for idiopathic retinal vasculitis, aneurysms, and neuroretinitis: favorable results
Ranitidine Hydrochloride-loaded Ethyl Cellulose and Eudragit RS 100 Buoyant Microspheres: Effect of pH Modifiers
Ranibizumab treatment in patients with neovascular age-related macular degeneration and very low vision
Ranibizumab for retinal arterial macroaneurysms
Ranimustine, ifosfamide, procarbazine, dexamethasone, and etoposide therapy for central nervous system recurrence of diffuse large B-cell lymphoma in patients with poor performance status: a pilot study
Ranibizumab plus Verteporfin Photodynamic Therapy in Neovascular Age-Related Macular Degeneration: 12 Months of Retreatment and Vision Outcomes from a Randomized Study
Ranibizumab Treatment in Age-Related Macular Degeneration: A Meta-Analysis of One-Year Results
Ranibizumab for exudative AMD in a clinical setting: differences between 2007 and 2010
Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration The CATT Research Group
Ranibizumab Treatment Administered as Needed for Occult and Minimally Classic Neovascular Membranes in Age-Related Macular Degeneration
Ranibizumab monotherapy for sub-foveal haemorrhage secondary to choroidal neovascularisation in age-related macular degeneration
Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: a systematic review and economic evaluation
Ranibizumab according to need: A treatment for age-related macular degeneration